Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjuvant V940 plus pembrolizumab versus placebo plus pembrolizumab after neoadjuvant pembrolizumab and platinum-doublet chemotherapy in resectable NSCLC without pCR
MOH_2024-09-26_013540Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Adjuvant pembrolizumab + V940 with Adjuvant pembrolizumab + placebo (2 arms). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-09-26_013540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-26_013540.